Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
Identifieur interne : 003793 ( PubMed/Checkpoint ); précédent : 003792; suivant : 003794Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
Auteurs : Kay Lee Park ; Robert J. Goldberg ; Frederick A. Anderson ; José L Pez-Send N [Espagne] ; Gilles Montalescot [France] ; David Brieger [Australie] ; Kim A. Eagle ; Allison Wyman ; Joel M. GoreSource :
- The American journal of medicine [ 1555-7162 ] ; 2014.
Descripteurs français
- KwdFr :
- Administration par voie intraveineuse, Administration par voie orale, Adolescent, Adulte, Adulte d'âge moyen, Analyse multivariée, Antagonistes bêta-adrénergiques (administration et posologie), Antagonistes bêta-adrénergiques (usage thérapeutique), Calendrier d'administration des médicaments, Enregistrements, Femelle, Humains, Infarctus du myocarde (), Infarctus du myocarde (diagnostic), Infarctus du myocarde (mortalité), Infarctus du myocarde (traitement médicamenteux), Jeune adulte, Modèles logistiques, Mortalité hospitalière, Mâle, Résultat thérapeutique, Score de propension, Sujet âgé, Sujet âgé de 80 ans ou plus, Électrocardiographie.
- MESH :
- administration et posologie : Antagonistes bêta-adrénergiques.
- diagnostic : Infarctus du myocarde.
- mortalité : Infarctus du myocarde.
- traitement médicamenteux : Infarctus du myocarde.
- usage thérapeutique : Antagonistes bêta-adrénergiques.
- Administration par voie intraveineuse, Administration par voie orale, Adolescent, Adulte, Adulte d'âge moyen, Analyse multivariée, Calendrier d'administration des médicaments, Enregistrements, Femelle, Humains, Infarctus du myocarde, Jeune adulte, Modèles logistiques, Mortalité hospitalière, Mâle, Résultat thérapeutique, Score de propension, Sujet âgé, Sujet âgé de 80 ans ou plus, Électrocardiographie.
English descriptors
- KwdEn :
- Administration, Intravenous, Administration, Oral, Adolescent, Adrenergic beta-Antagonists (administration & dosage), Adrenergic beta-Antagonists (therapeutic use), Adult, Aged, Aged, 80 and over, Drug Administration Schedule, Electrocardiography, Female, Hospital Mortality, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Myocardial Infarction (complications), Myocardial Infarction (diagnosis), Myocardial Infarction (drug therapy), Myocardial Infarction (mortality), Propensity Score, Registries, Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Adrenergic beta-Antagonists.
- chemical , therapeutic use : Adrenergic beta-Antagonists.
- complications : Myocardial Infarction.
- diagnosis : Myocardial Infarction.
- drug therapy : Myocardial Infarction.
- mortality : Myocardial Infarction.
- Administration, Intravenous, Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Drug Administration Schedule, Electrocardiography, Female, Hospital Mortality, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Propensity Score, Registries, Treatment Outcome, Young Adult.
Abstract
Current guidelines recommend early oral beta-blocker administration in the management of acute coronary syndromes for patients who are not at high risk of complications.
DOI: 10.1016/j.amjmed.2014.02.009
PubMed: 24561113
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24561113Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).</title><author><name sortKey="Park, Kay Lee" sort="Park, Kay Lee" uniqKey="Park K" first="Kay Lee" last="Park">Kay Lee Park</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="Goldberg, Robert J" sort="Goldberg, Robert J" uniqKey="Goldberg R" first="Robert J" last="Goldberg">Robert J. Goldberg</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="Anderson, Frederick A" sort="Anderson, Frederick A" uniqKey="Anderson F" first="Frederick A" last="Anderson">Frederick A. Anderson</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="L Pez Send N, Jose" sort="L Pez Send N, Jose" uniqKey="L Pez Send N J" first="José" last="L Pez-Send N">José L Pez-Send N</name><affiliation wicri:level="3"><nlm:affiliation>Cardiology Department, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Cardiology Department, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name><affiliation wicri:level="1"><nlm:affiliation>Concord Repatriation General Hospital, Coronary Care Unit, Concord, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Concord Repatriation General Hospital, Coronary Care Unit, Concord, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Eagle, Kim A" sort="Eagle, Kim A" uniqKey="Eagle K" first="Kim A" last="Eagle">Kim A. Eagle</name><affiliation><nlm:affiliation>University of Michigan Health System, Ann Arbor.</nlm:affiliation><wicri:noCountry code="subField">Ann Arbor</wicri:noCountry></affiliation></author><author><name sortKey="Wyman, Allison" sort="Wyman, Allison" uniqKey="Wyman A" first="Allison" last="Wyman">Allison Wyman</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="Gore, Joel M" sort="Gore, Joel M" uniqKey="Gore J" first="Joel M" last="Gore">Joel M. Gore</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester. Electronic address: joel.gore@umassmemorial.org.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24561113</idno><idno type="pmid">24561113</idno><idno type="doi">10.1016/j.amjmed.2014.02.009</idno><idno type="wicri:Area/PubMed/Corpus">003756</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003756</idno><idno type="wicri:Area/PubMed/Curation">003642</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003642</idno><idno type="wicri:Area/PubMed/Checkpoint">003642</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003642</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).</title><author><name sortKey="Park, Kay Lee" sort="Park, Kay Lee" uniqKey="Park K" first="Kay Lee" last="Park">Kay Lee Park</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="Goldberg, Robert J" sort="Goldberg, Robert J" uniqKey="Goldberg R" first="Robert J" last="Goldberg">Robert J. Goldberg</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="Anderson, Frederick A" sort="Anderson, Frederick A" uniqKey="Anderson F" first="Frederick A" last="Anderson">Frederick A. Anderson</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="L Pez Send N, Jose" sort="L Pez Send N, Jose" uniqKey="L Pez Send N J" first="José" last="L Pez-Send N">José L Pez-Send N</name><affiliation wicri:level="3"><nlm:affiliation>Cardiology Department, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Cardiology Department, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name><affiliation wicri:level="1"><nlm:affiliation>Concord Repatriation General Hospital, Coronary Care Unit, Concord, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Concord Repatriation General Hospital, Coronary Care Unit, Concord, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Eagle, Kim A" sort="Eagle, Kim A" uniqKey="Eagle K" first="Kim A" last="Eagle">Kim A. Eagle</name><affiliation><nlm:affiliation>University of Michigan Health System, Ann Arbor.</nlm:affiliation><wicri:noCountry code="subField">Ann Arbor</wicri:noCountry></affiliation></author><author><name sortKey="Wyman, Allison" sort="Wyman, Allison" uniqKey="Wyman A" first="Allison" last="Wyman">Allison Wyman</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author><author><name sortKey="Gore, Joel M" sort="Gore, Joel M" uniqKey="Gore J" first="Joel M" last="Gore">Joel M. Gore</name><affiliation><nlm:affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester. Electronic address: joel.gore@umassmemorial.org.</nlm:affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry></affiliation></author></analytic><series><title level="j">The American journal of medicine</title><idno type="eISSN">1555-7162</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravenous</term><term>Administration, Oral</term><term>Adolescent</term><term>Adrenergic beta-Antagonists (administration & dosage)</term><term>Adrenergic beta-Antagonists (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Administration Schedule</term><term>Electrocardiography</term><term>Female</term><term>Hospital Mortality</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Myocardial Infarction (complications)</term><term>Myocardial Infarction (diagnosis)</term><term>Myocardial Infarction (drug therapy)</term><term>Myocardial Infarction (mortality)</term><term>Propensity Score</term><term>Registries</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Administration par voie orale</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse multivariée</term><term>Antagonistes bêta-adrénergiques (administration et posologie)</term><term>Antagonistes bêta-adrénergiques (usage thérapeutique)</term><term>Calendrier d'administration des médicaments</term><term>Enregistrements</term><term>Femelle</term><term>Humains</term><term>Infarctus du myocarde ()</term><term>Infarctus du myocarde (diagnostic)</term><term>Infarctus du myocarde (mortalité)</term><term>Infarctus du myocarde (traitement médicamenteux)</term><term>Jeune adulte</term><term>Modèles logistiques</term><term>Mortalité hospitalière</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Score de propension</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Électrocardiographie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adrenergic beta-Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic beta-Antagonists</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antagonistes bêta-adrénergiques</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Myocardial Infarction</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Myocardial Infarction</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infarctus du myocarde</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Myocardial Infarction</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Myocardial Infarction</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infarctus du myocarde</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infarctus du myocarde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes bêta-adrénergiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravenous</term><term>Administration, Oral</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Administration Schedule</term><term>Electrocardiography</term><term>Female</term><term>Hospital Mortality</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Propensity Score</term><term>Registries</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Administration par voie orale</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse multivariée</term><term>Calendrier d'administration des médicaments</term><term>Enregistrements</term><term>Femelle</term><term>Humains</term><term>Infarctus du myocarde</term><term>Jeune adulte</term><term>Modèles logistiques</term><term>Mortalité hospitalière</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Score de propension</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Électrocardiographie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Current guidelines recommend early oral beta-blocker administration in the management of acute coronary syndromes for patients who are not at high risk of complications.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24561113</PMID><DateCreated><Year>2014</Year><Month>05</Month><Day>26</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-7162</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of medicine</Title><ISOAbbreviation>Am. J. Med.</ISOAbbreviation></Journal><ArticleTitle>Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).</ArticleTitle><Pagination><MedlinePgn>503-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2014.02.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9343(14)00140-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current guidelines recommend early oral beta-blocker administration in the management of acute coronary syndromes for patients who are not at high risk of complications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from patients enrolled between 2000 and 2007 in the Global Registry of Acute Coronary Events (GRACE) were used to evaluate hospital outcomes in 3 cohorts of patients admitted with ST-elevation myocardial infarction, based on beta-blocker use (early [first 24 hours] intravenous (IV) [± oral], only early oral, or delayed [after first 24 hours]).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 13,110 patients with ST-elevation myocardial infarction, 21% received any early IV beta-blockers, 65% received only early oral beta-blockers, and 14% received delayed (>24 hours) beta-blockers. Higher systolic blood pressure, higher heart rate, and chronic beta-blocker use were independent predictors of early beta-blocker use. Early beta-blocker use was less likely in older patients, patients with moderate to severe left ventricular dysfunction, and in those presenting with inferior myocardial infarction or Killip class II or III heart failure. IV beta-blocker use and delayed beta-blocker use were associated with higher rates of cardiogenic shock, sustained ventricular fibrillation/ventricular tachycardia, and acute heart failure, compared with oral beta-blocker use. In-hospital mortality was increased with IV beta-blocker use (propensity score adjusted odds ratio, 1.41; 95% confidence interval, 1.03-1.92) but significantly reduced with delayed beta-blocker administration (propensity adjusted odds ratio, 0.44; 95% confidence interval, 0.26-0.74).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early beta-blocker use is common in patients presenting with ST-elevation myocardial infarction, with oral administration being the most prevalent. Oral beta-blockers were associated with a decrease in the risk of cardiogenic shock, ventricular arrhythmias, and acute heart failure. However, the early receipt of any form of beta-blockers was associated with an increase in hospital mortality.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kay Lee</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Sendón</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montalescot</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brieger</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Concord Repatriation General Hospital, Coronary Care Unit, Concord, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eagle</LastName><ForeName>Kim A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>University of Michigan Health System, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyman</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gore</LastName><ForeName>Joel M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research, University of Massachusetts Medical School, Worcester. Electronic address: joel.gore@umassmemorial.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Global Registry of Acute Coronary Events Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med</MedlineTA><NlmUniqueID>0267200</NlmUniqueID><ISSNLinking>0002-9343</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical outcomes</Keyword><Keyword MajorTopicYN="N">Intravenous beta-blockers</Keyword><Keyword MajorTopicYN="N">Oral beta-blockers</Keyword><Keyword MajorTopicYN="N">ST-elevation myocardial infarction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>02</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>02</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24561113</ArticleId><ArticleId IdType="pii">S0002-9343(14)00140-5</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2014.02.009</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Espagne</li><li>France</li></country><region><li>Communauté de Madrid</li><li>Île-de-France</li></region><settlement><li>Madrid</li><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Anderson, Frederick A" sort="Anderson, Frederick A" uniqKey="Anderson F" first="Frederick A" last="Anderson">Frederick A. Anderson</name><name sortKey="Eagle, Kim A" sort="Eagle, Kim A" uniqKey="Eagle K" first="Kim A" last="Eagle">Kim A. Eagle</name><name sortKey="Goldberg, Robert J" sort="Goldberg, Robert J" uniqKey="Goldberg R" first="Robert J" last="Goldberg">Robert J. Goldberg</name><name sortKey="Gore, Joel M" sort="Gore, Joel M" uniqKey="Gore J" first="Joel M" last="Gore">Joel M. Gore</name><name sortKey="Park, Kay Lee" sort="Park, Kay Lee" uniqKey="Park K" first="Kay Lee" last="Park">Kay Lee Park</name><name sortKey="Wyman, Allison" sort="Wyman, Allison" uniqKey="Wyman A" first="Allison" last="Wyman">Allison Wyman</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="L Pez Send N, Jose" sort="L Pez Send N, Jose" uniqKey="L Pez Send N J" first="José" last="L Pez-Send N">José L Pez-Send N</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name></region></country><country name="Australie"><noRegion><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003793 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003793 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24561113
|texte= Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24561113" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |